ArticleCureus2026
Prognostic Factors of Chinese Non-small Cell Lung Cancer Patients Receiving Best Supportive Care.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to identify prognostic factors for Chinese patients with non-small cell lung cancer (NSCLC) receiving best supportive care (BSC) alone. MATERIALS AND
methodsThis retrospective study investigated patients with newly diagnosed NSCLC who underwent staging fluorodeoxyglucose (FDG) positron emission tomography (PET) and CT at Queen Elizabeth Hospital between 1st January 2018 and 31st March 2024, and were managed exclusively with BSC, without surgery, radiotherapy, or systemic therapy. The inclusion criteria were the following: 1) histologically proven NSCLC, 2) Chinese ethnicity receiving BSC alone, and 3) regular clinical follow-up till death. Subjects were excluded if they had 1) a history of lung neoplasm, 2) a concurrent active neoplasm, 3) defaulted follow-up, or 4) life-threatening events at the first oncology consultation. Potential prognostic determinants were evaluated, including age, gender, performance status, comorbidities, smoking history, previous malignancy, lung tumor histology, serum tumor marker, maximum diameter, as well as maximum standardized uptake value (SUVmax) of the primary tumor, number of metastatic organs, and the presence of pleural/pericardial effusion. Univariate log-rank tests and multivariate Cox proportional hazards regression were performed. The rationale for BSC and the eventual causes of death were analyzed.
resultsUnivariate analysis identified male gender, poorer performance status, histology of NSCLC not otherwise specified, larger primary tumor, greater primary tumor SUVmax (higher FDG uptake in primary tumor), and the presence of pleural or pericardial effusion as negative prognostic factors. Subsequent multivariate Cox regression showed four factors retained independent statistical significance: gender, performance status, maximum tumor diameter, and the presence of pleural/pericardial effusion. Three major concerns for the patient's decision to opt for best supportive care were concerns regarding treatment side effects (32.1%), advanced age (25.9%), and poor performance status (17.3%).
conclusionThis study shows that gender, performance status, tumor diameter, and presence of pleural/pericardial effusion are significant prognostic factors of overall survival in NSCLC patients receiving BSC exclusively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.